CD19 and acute lymphoblastic leukemia: These pioneering studies catalyzed numerous clinical investigations examining various aspects of CAR design, T-cell manufacturing protocols, gene transfer methods, and treatment regimens, consistently demonstrating efficacy in CD19-directed CAR-T therapy for B-ALL patients [248].